Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Nuclear Medicine

  Free Subscription


Articles published in Brain

Retrieve available abstracts of 55 articles:
HTML format
Text format



Single Articles


    May 2018
  1. SMITH CB, Schmidt KC
    Measurement of regional rates of protein synthesis in human brain in vivo with L-[1-11C]-leucine PET.
    Brain. 2018 May 3. pii: 4992170. doi: 10.1093.
    PubMed     Text format    


  2. SMEETS JSJ, van Loon LJC
    Reply: Measurement of regional rates of protein synthesis in human brain in vivo with L-[1-11C]-leucine PET.
    Brain. 2018 May 3. pii: 4992171. doi: 10.1093.
    PubMed     Text format    


  3. HANSSON O, Mormino EC
    Is longitudinal tau PET ready for use in Alzheimer's disease clinical trials?
    Brain. 2018;141:1241-1244.
    PubMed     Text format    


    March 2018
  4. BOTHA H, Mantyh WG, Murray ME, Knopman DS, et al
    FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis.
    Brain. 2018 Mar 12. pii: 4929906. doi: 10.1093.
    PubMed     Text format     Abstract available


  5. JACK CR JR, Wiste HJ, Schwarz CG, Lowe VJ, et al
    Longitudinal tau PET in ageing and Alzheimer's disease.
    Brain. 2018 Mar 12. pii: 4929907. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2017
  6. SOMMERAUER M, Fedorova TD, Hansen AK, Knudsen K, et al
    Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study.
    Brain. 2017 Dec 18. pii: 4759463. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  7. GAXIOLA-VALDEZ I, Singh S, Perera T, Sandy S, et al
    Seizure onset zone localization using postictal hypoperfusion detected by arterial spin labelling MRI.
    Brain. 2017;140:2895-2911.
    PubMed     Text format     Abstract available


    October 2017
  8. BEJANIN A, Schonhaut DR, La Joie R, Kramer JH, et al
    Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Brain. 2017 Oct 7. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2017
  9. DATTA G, Colasanti A, Rabiner EA, Gunn RN, et al
    Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis.
    Brain. 2017 Sep 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. SCHOLL M, Ossenkoppele R, Strandberg O, Palmqvist S, et al
    Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease.
    Brain. 2017;140:2286-2294.
    PubMed     Text format     Abstract available


    August 2017
  11. AYTON S, Fazlollahi A, Bourgeat P, Raniga P, et al
    Cerebral quantitative susceptibility mapping predicts amyloid-beta-related cognitive decline.
    Brain. 2017;140:2112-2119.
    PubMed     Text format     Abstract available


  12. HONG SJ, Bernhardt BC, Gill RS, Bernasconi N, et al
    The spectrum of structural and functional network alterations in malformations of cortical development.
    Brain. 2017;140:2133-2143.
    PubMed     Text format     Abstract available


  13. CHENNU S, Annen J, Wannez S, Thibaut A, et al
    Brain networks predict metabolism, diagnosis and prognosis at the bedside in disorders of consciousness.
    Brain. 2017;140:2120-2132.
    PubMed     Text format     Abstract available


    July 2017
  14. TOUSSEYN S, Krishnan B, Wang ZI, Wongwiangjunt S, et al
    Connectivity in ictal single photon emission computed tomography perfusion: a cortico-cortical evoked potential study.
    Brain. 2017;140:1872-1884.
    PubMed     Text format     Abstract available


  15. YEW B, Nation DA
    Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
    Brain. 2017;140:1987-2001.
    PubMed     Text format     Abstract available


  16. CHARIDIMOU A, Boulouis G, Gurol ME, Ayata C, et al
    Emerging concepts in sporadic cerebral amyloid angiopathy.
    Brain. 2017;140:1829-1850.
    PubMed     Text format     Abstract available


    May 2017
  17. PARBO P, Ismail R, Hansen KV, Amidi A, et al
    Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease.
    Brain. 2017 May 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. BUTCHER NJ, Marras C, Pondal M, Rusjan P, et al
    Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease.
    Brain. 2017;140:1371-1383.
    PubMed     Text format     Abstract available


  19. TOSUN D, Landau S, Aisen PS, Petersen RC, et al
    Association between tau deposition and antecedent amyloid-beta accumulation rates in normal and early symptomatic individuals.
    Brain. 2017;140:1499-1512.
    PubMed     Text format     Abstract available


    March 2017
  20. ROBERTS BR, Lind M, Wagen AZ, Rembach A, et al
    Biochemically-defined pools of amyloid-beta in sporadic Alzheimer's disease: correlation with amyloid PET.
    Brain. 2017 Mar 5. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  21. BANERJEE G, Kim HJ, Fox Z, Jager HR, et al
    MRI-visible perivascular space location is associated with Alzheimer's disease independently of amyloid burden.
    Brain. 2017 Feb 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. REEVES S, McLachlan E, Bertrand J, Antonio FD, et al
    Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
    Brain. 2017 Feb 4. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2017
  23. PASSAMONTI L, Vazquez Rodriguez P, Hong YT, Allinson KS, et al
    18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.
    Brain. 2017 Jan 24. pii: aww340. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. FAN Z, Brooks DJ, Okello A, Edison P, et al
    An early and late peak in microglial activation in Alzheimer's disease trajectory.
    Brain. 2017 Jan 24. pii: aww349. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. ONO M, Sahara N, Kumata K, Ji B, et al
    Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.
    Brain. 2017 Jan 12. pii: aww339. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. PONTECORVO MJ, Devous MD Sr, Navitsky M, Lu M, et al
    Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Brain. 2017 Jan 11. pii: aww334. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. SCHOBERL F, Feil K, Xiong G, Bartenstein P, et al
    Pathological ponto-cerebello-thalamo-cortical activations in primary orthostatic tremor during lying and stance.
    Brain. 2017;140.
    PubMed     Text format     Abstract available


    December 2016
  28. KAWANO H, Bivard A, Lin L, Ma H, et al
    Perfusion computed tomography in patients with stroke thrombolysis.
    Brain. 2016 Dec 31. pii: aww338. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2016
  29. O'SULLIVAN MJ, Vann SD
    Amyloid imaging and Alzheimer's disease: the unsolved cases.
    Brain. 2016;139.
    PubMed     Text format    


    July 2016
  30. LEWCZUK P, Kornhuber J
    Do we still need positron emission tomography for early Alzheimer's disease diagnosis?
    Brain. 2016.
    PubMed     Text format    


  31. PALMQVIST S, Mattsson N, Hansson O
    Reply: Do we still need positron emission tomography for early Alzheimer's disease diagnosis?
    Brain. 2016.
    PubMed     Text format    


    June 2016
  32. SMITH R, Puschmann A, Scholl M, Ohlsson T, et al
    18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers.
    Brain. 2016.
    PubMed     Text format     Abstract available


  33. CHETELAT G, Ossenkoppele R, Villemagne VL, Perrotin A, et al
    Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease.
    Brain. 2016.
    PubMed     Text format     Abstract available


  34. GORDON BA, Friedrichsen K, Brier M, Blazey T, et al
    The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging.
    Brain. 2016.
    PubMed     Text format     Abstract available


    May 2016
  35. OH H, Madison C, Baker S, Rabinovici G, et al
    Dynamic relationships between age, amyloid-beta deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.
    Brain. 2016.
    PubMed     Text format     Abstract available


  36. HANSEN AK, Knudsen K, Lillethorup TP, Landau AM, et al
    In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Brain. 2016.
    PubMed     Text format     Abstract available


  37. SARAZIN M, Lagarde J, Bottlaender M
    Distinct tau PET imaging patterns in typical and atypical Alzheimer's disease.
    Brain. 2016;139.
    PubMed     Text format    


  38. THAL DR, Vandenberghe R
    Monitoring the progression of Alzheimer's disease with tau-PET.
    Brain. 2016;139.
    PubMed     Text format    


    April 2016
  39. RABINOVICI GD
    Amyloid biomarkers: pushing the limits of early detection.
    Brain. 2016;139.
    PubMed     Text format    


    March 2016
  40. HAMELIN L, Lagarde J, Dorothee G, Leroy C, et al
    Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging.
    Brain. 2016.
    PubMed     Text format     Abstract available


  41. OSSENKOPPELE R, Schonhaut DR, Scholl M, Lockhart SN, et al
    Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Brain. 2016.
    PubMed     Text format     Abstract available


  42. PALMQVIST S, Mattsson N, Hansson O
    Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography.
    Brain. 2016.
    PubMed     Text format     Abstract available


  43. SCHWARZ AJ, Yu P, Miller BB, Shcherbinin S, et al
    Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
    Brain. 2016.
    PubMed     Text format     Abstract available


  44. SCHOTT JM, Fox NC
    Inflammatory changes in very early Alzheimer's disease: friend, foe, or don't know?
    Brain. 2016;139.
    PubMed     Text format    


    January 2016
  45. RODRIGUEZ-VIEITEZ E, Saint-Aubert L, Carter SF, Almkvist O, et al
    Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
    Brain. 2016.
    PubMed     Text format     Abstract available


  46. JAGUST W
    Is amyloid-beta harmful to the brain? Insights from human imaging studies.
    Brain. 2016;139.
    PubMed     Text format     Abstract available


    November 2015
  47. SCHOLS L, Reimold M, Seidel K, Globas C, et al
    No parkinsonism in SCA2 and SCA3 despite severe neurodegeneration of the dopaminergic substantia nigra.
    Brain. 2015;138.
    PubMed     Text format     Abstract available


    October 2015
  48. FAN Z, Okello AA, Brooks DJ, Edison P, et al
    Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


  49. MCCARTHY A, Lonergan R, Olszewska DA, O'Dowd S, et al
    Closing the tau loop: the missing tau mutation.
    Brain. 2015;138.
    PubMed     Text format     Abstract available


  50. NICCOLINI F, Foltynie T, Reis Marques T, Muhlert N, et al
    Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease.
    Brain. 2015;138.
    PubMed     Text format     Abstract available


  51. QAMHAWI Z, Towey D, Shah B, Pagano G, et al
    Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease.
    Brain. 2015;138.
    PubMed     Text format     Abstract available


  52. NICCOLINI F, Haider S, Reis Marques T, Muhlert N, et al
    Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease.
    Brain. 2015;138.
    PubMed     Text format     Abstract available


    September 2015
  53. PORTELIUS E, Zetterberg H, Skillback T, Tornqvist U, et al
    Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


    August 2015
  54. FRINGS L, Hellwig S, Spehl TS, Bormann T, et al
    Asymmetries of amyloid-beta burden and neuronal dysfunction are positively correlated in Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


    July 2015
  55. OSSENKOPPELE R, Pijnenburg YA, Perry DC, Cohn-Sheehy BI, et al
    The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features.
    Brain. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Nuclear Medicine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: